Second study will assess sarilumab for Covid-19
The Phase II/III trial will evaluate the IL-6 inhibitor in the treatment of Covid-19 patients in Italy, Spain, Germany, France, Japan, Canada and Russia. This is the second trial of its kind, following anecdotal reports that tocilizumab showed efficacy in treating these patients.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
More News: Actemra | Canada Health | COVID-19 | France Health | Germany Health | Health | Italy Health | Japan Health | Russia Health | Spain Health | Study